Curaleaf (OTCMKTS:CURLF) Announces Quarterly Earnings Results

Curaleaf (OTCMKTS:CURLF) announced its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.03, Zacks reports. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%.

Curaleaf Stock Performance

Shares of OTCMKTS:CURLF traded down $0.05 during midday trading on Thursday, reaching $2.43. 7,223,622 shares of the company traded hands, compared to its average volume of 563,108. Curaleaf has a 12 month low of $0.68 and a 12 month high of $5.05. The firm’s fifty day moving average price is $2.53 and its two-hundred day moving average price is $2.71. The company has a quick ratio of 0.71, a current ratio of 1.47 and a debt-to-equity ratio of 0.96. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of -7.60 and a beta of 0.74.

Analysts Set New Price Targets

CURLF has been the subject of several research reports. Alliance Global Partners reiterated a “buy” rating on shares of Curaleaf in a research note on Monday, December 22nd. ATB Cormark Capital Markets raised shares of Curaleaf to an “outperform” rating in a report on Tuesday, December 2nd. Finally, Zacks Research upgraded shares of Curaleaf from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy”.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.